Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, discusses acute myeloid leukemia (AML) in the context of the COVID-19 pandemic. The prevalence of healthcare disparities across the nation and globally makes AML treatment particularly challenging during the pandemic as many patients are immunocompromised. Because therapeutic treatment is time sensitive, AML patients cannot wait until COVID-19 is contained to seek medical care for testing, therapies, and procedures in the clinic.
